Webinar Reminder: AI in Healthcare: Adoption, Execution, and Outcomes in Drug Development | Wednesday, 08 June 2026

Research evidence excerpt

Webinar Reminder: AI in Healthcare: Adoption, Execution, and Outcomes in Drug Development | Wednesday, 08 June 2026

Etzer Darout, PhD, MBA, is a Managing Director and equity

research analyst covering the U.S. Small and Mid-Cap

Biotechnology sector, with over 10 years of sell-side

research experience. Before joining Barclays in June 2025,

Etzer spent three years at BMO Capital Markets as a

Managing Director and senior equity research analyst

covering the Biotechnology sector. Prior to his career on

Wall Street, he spent seven years at Pfizer, researching and

developing therapies for cardiovascular and metabolic

diseases. He graduated from Rutgers University with a PhD

in Organic Chemistry followed by post-doctoral research

at Scripps Research Institute in Jupiter, FL. Etzer also

holds an MBA from the UNC Kenan-Flagler Business

School.

View Analyst Page

Emily Field, CFA is a Director and Head of U.S.

Biopharmaceuticals equity research at Barclays. Joining

the bank’s London office in 2017, she previously served as

Head of the European Pharmaceuticals team, earning a #4

individual ranking in European Pharmaceuticals &

Biotechnology in the 2025 Extel survey. With more than

two decades experience across both buy-side and sell-side

roles, she has worked across multiple investing strategies

including risk arbitrage and equity long/short. Prior to

Barclays, Ms. Field held positions at UBS O’Connor and

Millennium Management. Originally hailing from Chicago,

Ms. Field holds a B.A. in Economics and History from Yale

University, graduating with distinction in both majors, and

is a CFA charterholder.

James Gordon is a Director and Head of the European

Pharma & Biotech Equity Research team at Barclays.

James joined Barclays in November 2025, having spent